The latest announcement is out from Ascendis Pharma ( (ASND) ).
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, clearing the path for the development and commercialization of products using TransCon technology in metabolic and cardiovascular diseases. This agreement grants Novo Nordisk an exclusive license to develop and market products targeting obesity and type 2 diabetes, with Ascendis set to receive a $100 million milestone payment, marking a significant step in their collaborative efforts in addressing major health conditions.
More about Ascendis Pharma
Ascendis Pharma A/S is a Danish biotechnology company specializing in the development of innovative therapies leveraging its proprietary TransCon technology platform. The company primarily focuses on developing treatments for endocrinology, oncology, and rare disease markets.
YTD Price Performance: 8.46%
Average Trading Volume: 487,265
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $8.16B
See more insights into ASND stock on TipRanks’ Stock Analysis page.
